Skip to main content
Premium Trial:

Request an Annual Quote

PharmiGene Gets OK to Market PGx Test for Carbamazepine Patients in Taiwan

NEW YORK (GenomeWeb News) – PharmiGene said today that the Department of Health in Taiwan has granted the firm approval to market its PG 1502 DNA detection kit on the island.
 
The test is used to identify patients at greater risk for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis, which are life-threatening adverse drug reactions. Carbamazepine is an anti-convulsant and mood-stabilizing drug used to treat epilepsy, biopolar disorder, and schizophrenia, among other conditions.
 
Last year, Taiwan’s DOH and the US Food and Drug Administration updated carbamazepine’s label to state that patients that have the HLA-B*1502 gene may be at higher risk of the two adverse reactions.
 
“With 40,000 new users of this drug every year in Taiwan alone, our kit will surely reduce this risk for a large number of patients,” PharmiGene CEO Jerome Shen said in a statement.
 
Taipei, Taiwan-based PharmiGene did not say whether it intends to seek FDA clearance of the test.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.